20020811
 Quiet Ends Week of Volatility As Traders Wait on Fed's Moves   By By Kopin Tan, The Wall Street Journal,  Aug 12, 2002  Put options in Biogen continued to trade briskly, with investors focused on buying Oct. 30 puts. These puts had traded actively all last week after it was suggested by certain advisers; with the trade, put buyers concerned about the biotechnology company's prospects and regulatory approval for a key psoriasis drug, Amevive, locked in the right to sell Biogen stock at $30 a share until mid-October. A Biogen representative said earlier last week that the company remained on track for Amevive's regulatory approval and launch.   
